The use of cannabis products was associated with “statistically significant improvements in IBD-specific outcomes” at three months.

“Medicinal cannabis was associated with improvements in depression and anxiety symptoms, as well as health-related quality of life,” investigators concluded.

Patients showed “statistically significant improvements” in a variety of domains, including sleep, anxiety, and stress.

Cannabis inhalation was associated with sustained improvements and side effects were “minimal.”

The study is among the first ever to assess cannabis’ influence on clinical outcomes in adult patients with ASD.

Investigators concluded, “Our results … may help to reduce [the] stigma experienced by people who use cannabis.”

Researchers observed that “cannabis use had a causal effect on lower incidence of renal cell carcinoma.”

“Our data suggest that whole-plant medical cannabis products are superior to isolated CBD products in the patients examined,” investigators reported.